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TULA, a recently identified UBA- and SH3-containing protein, has previously been shown to regulate cell signaling through protein tyrosine
kinases. In order to search for novel functions of TULA, we identified, using mass spectrometry, proteins associated with TULA. ABCE-1 also
known as RLI and HP68, a host factor of HIV-1 assembly, was found among TULA-associated proteins in these experiments. Considering an
important role of ABCE-1 in HIV-1 assembly, we were compelled to analyze the effect of TULA on HIV-1 biogenesis. Our study provides
evidence that TULA proteins substantially inhibit production of both sub-genomic and full-length HIV-1 viral particles and that the effect of
TULA is dependent on UBA domain-mediated interactions. The primary role of ABCE-1 in the effect of TULA appears to be the recruitment of
TULA to the sites of HIV-1 assembly where TULA interferes with the late steps of the HIV-1 life cycle, most likely by disrupting essential
ubiquitylation-dependent events that remain to be identified.
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We recently identified TULA among multiple proteins co-
purifying with c-Cbl from a T-cell line (Feshchenko et al.,
2004). TULA contains several distinct domains—a UBA do-
main capable of binding to ubiquitin and ubiquitylated proteins,Abbreviations: ABCE-1, ATP-binding cassette protein family E member 1;
FBS, fetal bovine serum; GFP, green fluorescent protein; HP68, human protein
68 kDa; LC-MS, liquid chromatography-mass spectrometry; ODG, β-octyl-D-
glucoside; PBS, phosphate-buffered saline; PGM, phosphoglyceromutase; PTK,
protein tyrosine kinase; RLI, RNase L inhibitor; SH3, Src homology 3 domain;
Sts, suppressor of T-cell receptor signaling; TULA, T-cell ubiquitin ligand;
UBA, ubiquitin-associated domain.
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doi:10.1016/j.virol.2007.10.012an SH3 domain capable of binding to proline-rich sequences,
including those of Cbl proteins, and a region initially termed
HCD, which has homology to phosphoglyceromutases (PGM)
(Carpino et al., 2004; Feshchenko et al., 2004; Kowanetz et al.,
2004; Wattenhofer et al., 2001) (Fig. 1). A mouse ortholog of
TULA (Sts-2) was identified, and mice deficient for this protein
and the second protein of this family were generated (Carpino
et al., 2002, 2004). Analysis of TULA expression in tissues and
cell lines demonstrated that this protein is expressed primarily in
T and B lymphocytes (Carpino et al., 2004; Feshchenko et al.,
2004). The second protein of this family Sts-1 (TULA-2) is
expressed ubiquitously (Carpino et al., 2002, 2004). (In this
report, we will use the term TULA for consistency with our
previous studies; Feshchenko et al., 2004.)
Several reports have implicated TULA in the regulation of
cell signaling mediated by protein tyrosine kinases (PTKs), in
which the UBA domain of TULA proteins appears to play an
Fig. 1. Schematic view of TULA and its mutants. UBA is a ubiquitin-associated
domain. SH3, an Src homology domain 3, binds to proline-rich motifs. HCD/
PGM is a region homologous to phosphoglyceromutases. [ΔUBA]TULA lacks
UBA as a result of a deletion. The W279L mutation inactivates TULA's SH3
domain.
Table 1
ABCE1-specific peptides identified in TULA immune complexes
Peptide sequence Amino acids No. of experiments
ILEDDLK 158–165 1/3
GTVGSILDR 182–190 1/3
NVEDLSGGELQR 213–224 2/3
VIVFDGVPSK 532–541 3/3
Immunoprecipitation with subsequent identification of associated proteins was
carried out as described in Materials and methods. Three individual experiments
were performed. The number of experiments in which a particular peptide was
detected is shown in the third column. Amino acid residues are numbered
according to the NCBI gi#108773782 sequence.
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Kowanetz et al., 2004). Since TULA proteins have been
described only recently, it is possible that they exert biologically
important effects other than the regulation of PTK-mediated
signaling. In order to address the issue of possible novel func-
tions of TULA, we decided to identify proteins associated with
TULA and to assess the involvement of TULA in cellular
events mediated by them. One of the proteins identified in these
experiments is the cellular factor of HIV-1 assembly termed
RLI, HP68 and ABCE-1 by different groups (Bisbal et al.,
1995; Kerr, 2004; Zimmerman et al., 2002).
Although HIV-1 Gag has self-assembling properties, multi-
ple studies indicate that host factors are involved in HIV-1
assembly in the cell (Gottlinger, 2001; Morikawa, 2003).
Furthermore, studies in a cell-free system suggested that the
assembly of HIV-1 particles is a stepwise, energy-dependent
process (Lingappa et al., 1997). The search for ATP-binding
molecular chaperones interacting with HIV-1 Gag led to the
discovery of HP68 (Human Protein 68 kDa) (Zimmerman et al.,
2002). HIV-1 Gag binds to HP68 immediately after translation
and remains associated with it in immature HIV-1 assembly
intermediates until the beginning of HIV-1 Gag processing
(Dooher et al., 2007; Zimmerman et al., 2002). Consistent with
these findings, assembly-incompetent HIV-1 Gag fails to bind
to HP68, whereas Gag from processing-defective HIV-1
exhibits prolonged association with HP68 (Dooher et al.,
2007; Lingappa et al., 2006; Zimmerman et al., 2002). Wild-
type, but not assembly-incompetent HIV-1 Gag exhibits sub-
stantial co-localization with HP68 at the HIV-1 assembly sites
on the plasma membrane (Dooher et al., 2007; Zimmerman
et al., 2002). Finally, a truncated form of HP68 blocks virion
production in vivo, and HP68 depletion significantly hinders
HIV-1 Gag assembly in vitro (Zimmerman et al., 2002).
HP68 contains two ATP/GTP-binding domains and may
act by bringing ATP to the immature HIV-1 intermediates
(Zimmerman et al., 2002) or by inducing conformational
changes in HIV-1 Gag, which are required for the late steps of
capsid formation (Datta et al., 2007), since the crystal structure
of HP68 suggests that these domains undergo an ATP-driven
clamp-like motion around a hinge region as if in a mechano-
chemical enzyme (Karcher et al., 2005).
HP68 was initially identified as the RNase L inhibitor (RLI)
(Bisbal et al., 1995). RNase L is an effector enzyme of the
cellular system that utilizes 2′,5′-linked oligoadenylates as a
major regulator, which is involved in the interferon-inducedantiviral and antiproliferative response (Bisbal et al., 2001;
Bisbal and Silverman, 2007; Flodstrom-Tullberg et al., 2005;
Silverman, 1994). Upregulation of the RLI expression by
viruses, including HIV-1 (Martinand et al., 1999), suggests that
HP68/RLI may have a two-fold positive effect on HIV-1 rep-
lication; first, as a host factor essential for capsid assembly, and
second, as a negative regulator of the antiviral enzyme RNase
L. Considering that bioinformatics analysis argues that the most
appropriate name for HP68/RLI is ABCE-1, since this protein is
the sole member of the ATP-binding cassette (ABC) protein
family E (Kerr, 2004), we will use the term ABCE-1 throughout
the text.
Results
Binding of TULA to ABCE-1
To date, very few TULA-binding partners are known
(Bertelsen et al., 2007; Feshchenko et al., 2004; Kowanetz
et al., 2004). In order to identify novel TULA-associated proteins,
FLAG-tagged TULAwas overexpressed in 293T cells, which do
not express endogenous TULA (Feshchenko et al., 2004), and
immunoprecipitated using anti-FLAG antibodies. The protein
content of the obtained immune complex was analyzed using
liquid chromatography-tandemmass spectrometry (LC-MS/MS).
In each of three replicate experiments we identified ABCE-1
(Table 1), which has previously been shown to be a key host factor
of HIV-1 assembly (Dooher and Lingappa, 2004; Lingappa et al.,
2006; Zimmerman et al., 2002). Considering the importance
of cellular factors involved in HIV-1 biogenesis, we decided to
further analyze a possible functional link between TULA and
ABCE-1.
To verify association of TULA and ABCE-1 using an inde-
pendent approach, we co-expressed FLAG-TULA and Myc-
ABCE-1 in 293T cells and immunoprecipitated TULA with
anti-FLAG antibody. This resulted in robust co-immunoprecip-
itation of ABCE-1 with TULA (Fig. 2A). When only TULA
was overexpressed, endogenous ABCE-1, which is expressed
ubiquitously (Aubry et al., 1996), also co-immunoprecipitated
with TULA in a dose-dependent fashion, mirroring the level of
TULA in the cells (Fig. 2B). To analyze the role of UBA and
SH3, two interactive domains of TULA, in this interaction, we
compared wild-type TULA and its mutant forms lacking either
UBA ([ΔUBA]TULA) or functional SH3 ([W279L]TULA)
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ABCE-1 co-immunoprecipitated not only with wild-type
TULA, but with both mutant forms as well (Fig. 2B).Fig. 2. Binding of TULA to ABCE-1. (A) 293T cells were transfected to
overexpress FLAG-tagged wild-type TULA and/or Myc-tagged ABCE-1 as
indicated at the top of the panel (8 μg of each expression plasmid per 100-mm
Petri dish). A GFP expression plasmid was added to monitor the efficiency of
transfection (0.5 μg per dish). Cells were homogenized in hypotonic buffer, and
the obtained homogenates were solubilized with ODG/TNE buffer 48 h after
transfection. Cell lysates were immunoprecipitated (IP) with anti-FLAG where
indicated at the top of the panel or used without immunoprecipitation
(WCL=whole cell lysates). Antibodies used in Western blotting (WB) and
the proteins detected are indicated at the left and the right of the panel,
respectively. The results of a representative experiment of three independent
experiments are shown. (B) 293T cells were infected with recombinant
adenovirus expressing wild-type (WT) or mutant TULA. Cells were lysed in
TNE buffer, and their WCLs or IPs were analyzed using Western blotting as
shown. The antibodies used and the proteins detected are indicated as described
in panel A. In this and subsequent experiments, a minor band migrating above
WT TULA and [W279L]TULA is a monoubiquitylated form of this protein
(Hoeller et al., 2006). The results of a representative experiment of three
independent experiments are shown. (C) 293T cells were transfected to
overexpress FLAG-tagged wild-type TULA or TULA-2 with or without Myc-
tagged ABCE-1 as indicated at the top of the panel (2 μg of each expression
plasmid plus 0.2 μg of GFP expression plasmid per well of a 6-well plate). Cells
were lysed in TNE buffer 36 h after transfection. Cell lysates were analyzed as
described in panel A. The results of a representative experiment of two
independent experiments are shown.Considering that TULA belongs to a two-protein family, we
assessed, using co-immunoprecipitation, the ability of its
homologue (Sts-1/TULA-2) to bind to ABCE-1. The results
of these experiments indicated that both TULA proteins are
capable of binding to ABCE-1 (Fig. 2C). Overall, our studies
indicate that TULA proteins and ABCE-1 physically interact
and that neither UBA nor SH3 of TULA appears to be essential
for this interaction.
Modulation of the expression of TULA proteins exerts an effect
on HIV-1 production
Because ABCE-1 is a crucial host factor of HIV-1 assembly,
we were compelled to study the effect of TULA proteins on
HIV-1 biogenesis. First, we assessed the effect of TULA on the
production of replication-incompetent GFP-expressing pseudo-
typed HIV-1 in 293T cells using a single-round infectivity assay
in Jurkat cells. The results of these experiments showed that
overexpression of wild-type TULA reduces the viral titer in
supernatants ∼3-fold as compared to that in the supernatants of
vector control cells. Whereas [ΔUBA]TULA failed to signif-
icantly modify virus production, [W279L]TULA reduced viral
titers to the same degree as wild-type TULA did (Fig. 3A). This
result indicated that the SH3 domain is dispensable for the
antiviral effect of TULA, while UBA is necessary for this effect.
Finally, TULA-2/Sts-1 reduced viral titers to a slightly higher
extent than TULA did (Fig. 3A). To assure that TULA proteins
were expressed in virus-producing 293T cells, their lysates were
analyzed using immunoblotting (Fig. 3B); all forms of TULA
were found to be expressed at a high level. The level of GFP
was constant throughout the experiment, indicating equal
transfection efficiency of different samples.
To determine whether TULA proteins affect virus production
or viral infectivity, we isolated virions from supernatants of
virus-producing cells and assessed virus production by detect-
ing p24, a Gag-derived protein packaged in the HIV-1 particles,
using immunoblotting. These experiments indicated that
production of virions by cells overexpressing either TULA or
TULA-2 was significantly reduced as compared to the produc-
tion of virions by vector control cells (Fig. 3B). The effects of
TULA mutants in these experiments were similar to those
detected using the single-round infectivity assay: wild-type
TULA and [W279L]TULA reduced the production of virions to
a similar degree, whereas the ability of [ΔUBA]TULA to affect
virus production was substantially weakened as compared to
that of wild-type TULA and of [W279L]TULA (Fig. 3B).
A simple explanation of the effect of TULA on the produc-
tion of HIV-1 would be a decrease in total expression of HIV-1
Gag in cells overexpressing TULA. To examine this possibility,
we analyzed HIV-1 Gag both in viral particles and cell lysates.
The experiment shown in Fig. 3C demonstrated a moderate (less
than 2-fold) effect exerted by TULA on the level of cellular
HIV-1 Gag (both Pr55Gag and total HIV-1 Gag). In contrast, the
effect of TULA on the amount of p24 and p17 proteins of
mature HIV-1 in viral pellets was profound (up to 10-fold).
These results argued that the effect of TULA on virus pro-
duction is not mediated simply by an overall decrease in HIV-1
Fig. 3. Effect of TULA proteins on the production of HIV-1. (A) 293T cells were co-transfected with the three plasmids required for the production of HIV-1 VSVG-
pseudotyped virus plus an expression plasmid for one of the examined proteins as indicated at the bottom of the panel (7.5 μg of each plasmid per 100-mm Petri dish).
Jurkat cells (2×105 in a 0.5-ml sample) were transduced with 10-μl aliquots of viral supernatant (corresponding to the linear infection range) in triplicates. Percentage
of infected Jurkat cells is plotted as mean±SD; vector control=100%. The results of a representative experiment of five independent experiments are shown. (B) TNE
lysates of virus-producing 293T cells and virus pellets from the experiment shown in panel Awere analyzed using Western blotting with the antibodies indicated at the
left of the panel. Anti-p24 mAb AG3.0 was used to probe p24. Proteins detected are indicated at the right of the panel. (C) 293T cells were transfected with all the
plasmids required for virus production and an expression plasmid for TULA, wild-type or mutant, as indicated at the top of the panel. Virions released were collected
and virus-producing 293T cells were homogenized and solubilized in RIPA buffer 48 h after transfection. Both virions and cell lysates were analyzed for HIV-1 Gag
expression using Western blotting. The antibodies used and the proteins detected are indicated as in panel B. Anti-p24 mAb AG3.0 was used to probe HIV-1 Gag in
WCL. Goat polyclonal anti-p24 (ViroStat) was used to probe p24 in virions. The result of a representative experiment of three independent experiments is shown.
(D) Cells were transfected, and their supernatants were harvested as described in panel A. Virus production was measured using a p24 antigen capture assay. The
results of a representative experiment of two independent experiments are plotted as mean±SD of duplicate measurements; vector control=100%. (E) Cells were
transfected to express HIV-1 Gag (pCMVΔ8.2) and TULA as indicated (6 μg of each plasmid per 100-mm dish) and treated with 20 μg cycloheximide (Sigma) per ml
at 40 h post-transfection. Samples of CHX-treated cells were collected and lysed in RIPA at times indicated. Proteins in whole cell lysates were analyzed usingWestern
blotting as indicated. Linear regression was carried out using the Prism software package (GraphPad, San Diego, CA). (F) CD4+HeLa cells were transfected with
TULA proteins as indicated and infected with the full-length replication-competent HIV-1 strain RF. Supernatants were harvested at times indicated, and virus
production was analyzed using a p24 antigen capture assay. Mean±SEM of duplicate measurements are shown.
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UBA, but not SH3 domain, is essential for the observed effect of
TULA.
To corroborate the results obtained using single-round
infectivity assays and anti-p24 immunoblotting of viral pellets,
we measured the amount of p24 in supernatants of virus-
producing 293T cells using a p24 antigen capture assay.
Consistent with the previous experiments, a substantial decrease
in the level of p24 in supernatants of virus-producing cells was
noticed (Fig. 3D). The effect of TULA proteins on the amount
of p24 in the supernatant was not as profound as that shown in
Figs. 3B and C, probably because a substantial part of p24 in thesupernatants is present in the soluble form (probably, due to
disintegration of virus-producing cells) and not in virions, thus
‘diluting’ the observed effect.
Taken together, the results shown in Figs. 3A–D indicate that
TULA proteins inhibit production of HIV-1-based viral
particles exerting a very modest effect on the intracellular
level of HIV-1 Gag. To further characterize the effect of TULA
on intracellular HIV-1 Gag, we determined how TULA affects
stability of HIV-1 Gag in 293T cells. The results of these
experiments indicated that TULA exerts no significant effect on
HIV-1 Gag half-life (Fig. 3E), thus confirming our previous
findings (Fig. 3C).
Fig. 4. Effect of TULA-2 depletion on the production of HIV-1. 293T cells were
co-transfected with TULA-2-specific or control siRNA twice with a 24-h interval
between transfections. The plasmids required for the production of HIV-1-based
VSVG-pseudotyped lentivirus (1.5 μg of each pMD.G and pCMVΔ8.2, 3 μg of
pCE per well of a 6-well plate) were transfected with the second batch of siRNA.
Supernatants of virus-producing cells were harvested. Cells were homogenized,
and the obtained homogenates were solubilized in RIPA buffer 40 h after second
transfection. (A) RIPA lysates were analyzed using Western blotting. The
proteins detected are indicated with arrowheads at the right of the panel. The
antibodies used are indicated at the left of the panel. Anti-p24 mAb AG3.0 was
used to probe HIV-1 Gag. (B) Cell supernatants were used to transduce Jurkat
cells (10 μl aliquots added to 2×105 cells in a total volume of 500 μl). Mean±SD
of triplicate measurements are shown; infectivity of control supernatant=100%.
The results of a representative experiment of two independent experiments are
shown.
Fig. 5. Effect of TULA on HIV-1 Gag processing. 293T cells were transfected to
express HIV-1 Gag and FLAG-tagged TULA in various combinations (8 μg of
each plasmid plus 0.5 μg of GFP expression vector per 100-mm Petri dish). The
pCMVΔ8.2 plasmid was used to express HIV-1 Gag. Cells were homogenized
in hypotonic buffer and solubilized in RIPA buffer 72 h after transfection. Cell
lysates were analyzed using Western blotting. The proteins detected and the
antibodies used are indicated at the left and at the right of the figure, respectively.
Anti-p24 mAb AG3.0 was used to probe HIV-1 Gag. The results of a
representative experiment of four independent experiments are shown.
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production of replication-competent full-length HIV-1 using
overexpression of TULA and TULA-2 in CD4+ HeLa cells.
(The cells were selected both to facilitate transfection of TULA-
encoding DNA and to support HIV-1 infection and replication.)
The results of these experiments indicated that replication of the
full-length T-tropic HIV-1 strain RF was decreased approxi-
mately 2- to 3-fold in cells transfected to express TULA pro-
teins (Fig. 3F). Therefore, TULA proteins are capable of
inhibiting not only production of sub-genomic HIV-1-basedvirus particles, but also production of virus particles formed by
replication-competent full-length HIV-1.
Considering that results obtained using overexpression
typically require validation by depletion of an endogenous
protein of interest, we depleted TULA-2 in 293T cells using the
RNAi approach. (Depletion of TULAwas not required, because
293T cells do not express TULA; Feshchenko et al., 2004.) The
depletion of TULA-2 was nearly complete (Fig. 4A) and sig-
nificantly upregulated HIV-1 production in siRNA-treated cells
as measured using the single-round infectivity assay (Fig. 4B).
The results shown in Fig. 4 indicate that TULA-2 depletion
increased infectivity of the produced HIV-1 by a factor of 4.4,
while affecting the levels of Pr55gag and p24 to a substantially
lower extent (increased 1.2- and 1.7-fold, respectively), thus
arguing that the effect of TULA-2 depletion was not mediated
simply by modulation of HIV-1 Gag expression. Taken together
with the results shown in Fig. 3, these findings are indicative of
a negative effect of TULA proteins on HIV-1 biogenesis.
Molecular basis of the effects of TULA on HIV-1 production
Since TULA inhibits production of HIV-1 without exerting a
significant effect on HIV-1 Gag expression, we analyzed the
pattern of HIV-1 Gag processing in 293T cells transfected to
overexpress TULA as being indicative of changes in HIV-1
maturation. These experiments revealed that the presence of
TULA typically resulted in the appearance of the p25 band
at 72 h post-transfection, which was never seen without
TULA overexpression (Fig. 5) or when [ΔUBA]TULA was
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shown to be indicative of the impairment of late steps of the
HIV-1 life cycle, such as budding and release (Demirov et al.,
2002; Gottlinger et al., 1991; Martin-Serrano and Bieniasz,
2003). These findings together with the lack of a substantial
effect of TULA proteins on the expression level of HIV-1 Gag
(see Figs. 3C, E and 5), argued that TULA acts on HIV-1
production by hampering late steps of the HIV-1 life cycle.
Considering that this effect of TULA may also be manifested
in changes of the intracellular localization of HIV-1 Gag, we
analyzed intracellular distribution of HIV-1 Gag in the cells
overexpressing TULA. First, we examined the effects of TULA
on localization of GFP-fused HIV-1 Gag, a fluorescent protein
which is fully capable of producing HIV-1 viral particles (Sherer
et al., 2003). In the absence of TULA co-expression, HIV-1
Gag-GFP showed punctate localization, primarily to the plasma
membrane-proximal area. Upon co-expression of wild-type
TULA, plasma membrane-proximal localization of HIV-1 Gag-
GFP was diminished, and HIV-1 Gag-GFP was accumulated, to
a substantial extent, in the perinuclear area. In contrast, [ΔUBA]
TULA did not affect HIV-1 Gag-GFP localization (Fig. 6).
Considering that intracellular distribution of HIV-1 Gag may be
influenced by other HIV-1 proteins, we next evaluated, using
immunofluorescence, the effect of TULA on HIV-1 Gag local-
ization in cells co-transfected with a TULA expression plasmid
and the pCMVΔ8.2 plasmid, which encodes all HIV-1 proteins
except for Env. In control cells, HIV-1 Gag was localized
primarily on the periphery, in the plasma membrane-proximal
area, whereas it showed uniform intracellular distribution with-
out any preference for the periphery in TULA-overexpressing
cells (Fig. 7A). Therefore, in both systems TULA perturbedFig. 6. Effect of TULA on the intracellular localization of HIV-1 Gag-GFP. HeLa c
[ΔUBA]TULA as indicated at the top of the figure. In the cells expressing HIV-1 G
plasmid. Cells were fixed and analyzed using a confocal microscope. The scale bar eq
of a representative experiment of two independent experiments is shown.intercellular distribution of HIV-1 Gag in a qualitatively similar
fashion. The higher extent of the effect of TULA on HIV-1 Gag-
GFP may be due to a difference between HIV-1 Gag and HIV-1
Gag-GFP expression levels or to the absence of other HIV-1
proteins in the system shown in Fig. 6.
Since many previous studies implicated CD63+ membrane
structures in trafficking of HIV-1 Gag and HIV-1 egress
(Deneka et al., 2007; Goff et al., 2003; Jolly and Sattentau,
2007; Jouvenet et al., 2006; Nydegger et al., 2006; Perlman and
Resh, 2006; Sherer et al., 2003; von Schwedler et al., 2003;
Welsch et al., 2007), we next evaluated co-localization of HIV-1
Gag with CD63, a marker of multivesicular bodies, which is
also present on plasma membrane invaginations that serve as
sites of productive HIV-1 particle assembly. Partial co-
localization of HIV-1 Gag with CD63 was observed in control
cells but was diminished upon overexpression of TULA
(Fig. 7B) in agreement with the notion that CD63+ compart-
ments are involved in HIV-1 production.
ABCE-1 recruits TULA to HIV-1 Gag
Since TULA binds to ABCE-1, it was possible to speculate
that TULA disrupts normal interactions between HIV-1 Gag and
ABCE-1, thus inhibiting the HIV-1 capsid assembly by ex-
cluding ABCE-1 from assembly intermediates. To evaluate this
possibility, we analyzed binding of HIV-1 Gag, ABCE-1 and
TULA using their co-immunoprecipitation from cells co-
expressing these proteins in various combinations (Fig. 8).
(GFP-tagged HIV-1 Gag was used to avoid co-migration of
Pr55gag with the heavy chain of anti-HIV-1 Gag antibodies.)
First, these experiments confirmed our results indicating thatells were transfected to express HIV-1 Gag-GFP and either wild-type TULA or
ag-GFP alone an empty plasmid was transfected instead of a TULA expression
uals 10 μm. Two representative fields are shown for each transfection. The result
Fig. 7. Effect of TULA on the intracellular localization of HIV-1 Gag. HeLa cells were transfected to express HIV-1 Gag (using pCMVΔ8.2) and wild-type TULA as
indicated at the left of each panel (2 μg of each plasmid per 60-mm dish). In the cells expressing HIV-1 Gag alone, an empty plasmid was transfected instead of a TULA
expression plasmid. Cells were fixed, stained with the antibodies against HIV-1 Gag and TULA (A) or against HIV-1 Gag and CD63 (B) as indicated at the top of each
panel and analyzed using a confocal microscope. The scale bar equals 10 μm. The result of a representative experiment of two independent experiments is shown.
16 E.V. Smirnova et al. / Virology 372 (2008) 10–23TULA binds to ABCE-1 in a UBA-independent fashion.
Second, they confirmed the earlier studies demonstrating
binding of ABCE-1 to HIV-1 Gag (Dooher et al., 2007;
Zimmerman et al., 2002). Third, they showed that TULA was
co-immunoprecipitated with HIV-1 Gag, consistent with the
ability of ABCE-1 to bind to both HIV-1 Gag and TULA.
However, these experiments failed to provide evidence of the
disruption of HIV-1 Gag-ABCE-1 interaction upon overexpres-
sion of TULA.
The ability of ABCE-1 to bind to both HIV-1 Gag and
TULA (Figs. 2 and 8) and the inability of TULA to disrupt
HIV-1 Gag-ABCE-1 binding (Fig. 8) argued that ABCE-1 mayact as an adaptor molecule that recruits TULA to HIV-1 Gag.
To examine this possibility, we analyzed, using immunoblot-
ting, distribution of HIV-1 Gag, TULA and ABCE-1 in cells
overexpressing these proteins in various combinations (Fig. 9).
Purity of membrane and cytosolic fractions was verified using
VLA-2α and GAPDH, respectively. GFP was used to verify
both the efficiency of transfection and the purity of cytosolic
fraction. As expected, Pr55gag was localized almost exclusive-
ly to the membrane, whereas ABCE-1 and TULA were found
both in the cytosol and on the membrane. We analyzed the
subcellular distribution of TULA by comparing the ratios of
membrane-associated TULA to cytosolic TULA in different
Fig. 8. Interactions of HIV-1 Gag, TULA and ABCE-1. 293T cells were
transfected to overexpress GFP-tagged HIV-1 Gag, WTorΔUBATULA, and/or
Myc-tagged ABCE-1 as indicated at the top of the panel (8 μg of each
expression plasmid per 100-mm Petri dish). Cell lysates were obtained 48 h after
transfection by homogenizing cells in TNE-L buffer; lysates were filtered
through a 0.45-μm filter. Cell lysates and immunoprecipitates were analyzed as
described in the legends to Figs. 2 and 3B. The results of a representative
experiment of six independent experiments are shown.
Fig. 9. Effect of HIV-1 Gag and ABCE-1 on the subcellular distribution of
TULA. 293T cells were transfected to overexpress HIV-1 Gag, FLAG-tagged
TULA and/or Myc-tagged ABCE-1 as indicated at the top of the panel (8 μg of
each expression plasmid per 100-mm Petri dish). Empty vector was added
where required to keep the total amount of DNA constant. GFP expression
plasmid was added to each sample to monitor the efficiency of transfection
(0.5 μg per 100-mm Petri dish). Cells were homogenized 48 h after transfection.
Membrane and cytosolic fractions were obtained using ultracentrifugation of
pre-cleared homogenate and analyzed using Western blotting. The proteins
detected and the antibodies used for detection are indicated at the right and at
the left of the corresponding panels, respectively. Anti-p24 mAb AG3.0 was
used to probe HIV-1 Gag. The level of membrane and cytosolic TULA in the
relevant samples has been quantified. The results of a representative experiment
of four independent experiments are shown. Assigning the value of 1.0 to the
ratio of membrane-associated TULA to cytosolic TULA in cells transfected to
express TULA alone, these ratios were 1.41±0.37, 0.99±0.21 and 1.84±0.56
(mean±SEM) for TULA/ABCE-1, TULA/GAG and TULA/ABCE-1/GAG
cells based on all four experiments.
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sample-to-sample variation due to the use of transient
expression. Our experiments indicated that the ratio of
membrane-associated TULA to cytosolic TULA showed a
tendency to increase when TULA was co-expressed with
ABCE-1 and, even more so, with both ABCE-1 and HIV-1
Gag (Fig. 9). A moderate increase in the amount of membrane-
localized TULA when ABCE-1 was overexpressed alone may
possibly be explained by TULA's binding to ABCE-1
associated with the membrane in a Gag-independent fashion.
Overall, the results shown in Figs. 8 and 9 suggested that
ABCE-1 facilitates the interaction between HIV-1 Gag and
TULA, while TULA exerts no substantial effect on the inter-
action between HIV-1 Gag and ABCE-1. These results are also
consistent with partial co-localization of TULA and HIV-1
Gag detected using immunofluorescence (Fig. 7A).
Discussion
The results presented in this report demonstrate that TULA
proteins are capable of inhibiting HIV-1 production. Although
recent results implicate ABCE-1 in protein translation (Chen
et al., 2006; Dong et al., 2004; Estevez et al., 2004; Kispalet al., 2005; Yarunin et al., 2005; Zhao et al., 2004), thus
making conceivable that TULA acts on HIV-1 biogenesis by
interfering with HIV-1 protein expression, our findings do not
support the involvement of this mechanism, since the effect of
modulation of the level of TULA proteins on HIV-1
production is much higher than its effect on the expression
of HIV-1 Gag (Figs. 3–5). Likewise, TULA neither affects
the stability of HIV-1 Gag (Fig. 3E) nor totally blocks pro-
cessing of HIV-1 Gag, instead slightly increasing the ratio of
p24 and p41 to Pr55gag (Figs. 3E and 5). These results, taken
together with the ability of TULA to induce the appearance of
p25 (Fig. 5), a change in HIV-1 Gag processing pattern that is
consistent with a block in HIV-1 budding and release
(Demirov et al., 2002; Gottlinger et al., 1991; Martin-Serrano
and Bieniasz, 2003), indicate that TULA proteins inhibit late
steps of the HIV-1 life cycle. Importantly, our results indicate
that TULA proteins inhibit production of viral particles
by both sub-genomic and full-length replication-competent
HIV-1 (Fig. 3), arguing that this effect is biologically relevant.
It should be noted that overexpressed TULA proteins were
incapable of inhibiting HIV-1 infection at MOI 10-fold higher
than that used in the experiment presented in Fig. 3F (data
not shown). This may be due simply to the saturation of
TULA or to an active counter-effect of HIV-1.
The findings that TULA and TULA-2, when overexpressed,
induce similar effects on HIV-1 production as judged using
multiple experimental approaches (Figs. 3A, B, D, F) and that
the effect of TULA-2 depletion, i.e. an increase in HIV-1
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is consistent with the effect of overexpressed proteins (Fig. 4)
argue that the observed inhibitory effect is common for both
family members. This finding is in agreement with the critical
role of the UBA domain in the observed effects (Figs. 3A–C),
since the structure and ubiquitin-binding ability are similar for
the UBA domains of TULA and TULA-2 (Carpino et al., 2004;
Feshchenko et al., 2004; Hoeller et al., 2006; Kowanetz et al.,
2004). The essential role of the UBA domain in the TULA-
dependent inhibition of HIV-1 production argues that TULA is
likely to act by disrupting the ubiquitylation-mediated events
critical for the late steps of the HIV-1 life cycle.
Several lines of evidence, including the impairment of HIV-1
release from HIV-1 Gag-producing cells by decreasing the
cellular pool of ubiquitin or by mutating multiple HIV-1 Gag
ubiquitin-acceptor sites, suggest a functional contribution of
ubiquitylation to retroviral budding, in general, and that of HIV-1,
in particular (Gottwein et al., 2006; Gottwein and Krausslich,
2005; Jager et al., 2007; Patnaik et al., 2000; Schubert et al., 2000;
Strack et al., 2000, 2002). The molecular basis of this effect is not
fully understood but may be related to the recruitment, for
example, to ubiquitylated HIV-1 Gag, of cellular factors that are
essential for both virus budding and the formation of intraluminal
vesicles of the multivesicular bodies, such as the ESCRT-I
complex (Bieniasz, 2006; Morita and Sundquist, 2004). HIV-1
Gag appears to interact with the ESCRT-I complex through
Tsg101, a protein binding to both the PTAP motif and ubiquitin
(Garrus et al., 2001; Goff et al., 2003; Stuchell et al., 2004; von
Schwedler et al., 2003). Although binding of Tsg101 to HIV-1
Gag may involve several different interactions, it has been shown
that the loss of ubiquitin binding by Tsg101 prevents its
interaction with HIV-1 Gag and greatly reduces production of
virus-like particles (Goff et al., 2003). Therefore, TULA may
interfere with the interactions between HIV-1 Gag and Tsg101 by
competing with Tsg101 for a crucial ubiquitin. It should be noted
that this ubiquitin may be attached to proteins other than HIV-1
Gag. For example, the novel E3 ubiquitin-protein ligase POSH
has been shown to be essential for HIV-1 production, while
apparently incapable of ubiquitylating HIV-1 Gag (Alroy et al.,
2005). Finally, we cannot rule out that TULA exerts its effect on
the late steps of HIV-1 life cycle by regulating the level of
ubiquitylation of a certain crucial protein, which may or may not
be HIV-1 Gag.
The location of sites of productive HIV-1 particle assembly
has been a matter of controversy. Multiple studies suggested
previously that assembly in late endosomes is a general feature
of retroviruses, including HIV-1 (Blot et al., 2004; Goff et al.,
2003; Nydegger et al., 2003; Pelchen-Matthews et al., 2003;
Perlman and Resh, 2006; Sherer et al., 2003). However, several
recent studies demonstrated that the primary site of productive
HIV-1 particle assembly in various cell types is plasma mem-
brane and that the presence of HIV-1 particles in late endosomes
is due to their internalization from the plasma membrane
(Deneka et al., 2007; Jolly and Sattentau, 2007; Jouvenet et al.,
2006; Nydegger et al., 2006; Welsch et al., 2007). Notably,
these studies indicate that the plasma membrane structures in
which HIV-1 particles are assembled and budded are positivefor the endosomal marker CD63, thus rendering CD63+
compartments critical for HIV-1 biogenesis according to both
models of HIV-1 Gag trafficking. Therefore, we characterized
the effect of TULA on the critical features of intracellular
localization of HIV-1 Gag, i.e. its plasma membrane/intracel-
lular distribution and its co-localization with CD63. These
experiments revealed that TULA diminishes both localization
of HIV-1 Gag to the plasma membrane-proximal area (Figs. 6
and 7A) and its co-localization with CD63 (Fig. 7B), thus being
consistent with the findings demonstrating inhibition of the late
steps of the HIV-1 life cycle by TULA proteins. The identity of
compartments to which HIV-1 Gag is localized in the presence
of TULA remains to be determined.
Our results provide no direct support to the hypothesis that
TULA inhibits HIV-1 biogenesis by disrupting the interaction
of ABCE-1 with HIV-1 assembly intermediates, while suggest-
ing the role of ABCE-1 as a recruiter of TULA to HIV-1 Gag
(Figs. 8 and 9). The notion that TULA is recruited to HIV-1 Gag
is consistent with the partial co-localization of these proteins
(Fig. 7A). The translocation of TULA to the sites of HIV-1
assembly, although partial, is likely to be important for
providing specificity to the observed effect of TULA, since
TULA proteins appear to exert multiple UBA-mediated effects
(Feshchenko et al., 2004; Hoeller et al., 2006; Kowanetz et al.,
2004). It should also be noted that the obtained results cannot
entirely rule out the possibility that TULA inhibits HIV-1
biogenesis by adversely affecting HIV-1 Gag-ABCE-1 interac-
tions, because it is conceivable that TULA interferes with these
interactions and hence with the biological effect of ABCE-1
without significantly decreasing co-immunoprecipitation of
HIV-1 Gag and ABCE-1. Clearly, the molecular basis of the
functional link between TULA and ABCE-1 in the observed
phenomena remains to be understood.
Notably, TULA is not the sole protein capable of exerting a
negative effect on HIV-1 biogenesis; multiple proteins have
been shown to mediate cellular defense against HIV-1 infection.
Thus, APOBEC-family proteins act by hypermutating nascent
reverse transcripts of HIV-1 (Gaddis et al., 2003; Harris et al.,
2003; Lecossier et al., 2003; Mangeat et al., 2003; Mariani et al.,
2003; Zhang et al., 2003) and by preventing the accumulation of
reverse transcripts (Bishop et al., 2006; Newman et al., 2005).
TRIM5α, another intracellular anti-HIV factor, appears to act
by promoting rapid, premature disassembly of retroviral capsids
(Perez-Caballero et al., 2005; Stremlau et al., 2004, 2006, 2005;
Yap et al., 2004). OTK18 has been shown to act through
suppression of HIV-1 transcription (Carlson et al., 2004). TULA
proteins appear to inhibit the late steps of the HIV-1 life cycle
through a mechanism dissimilar to any of those known. It
remains to be determined whether the molecular basis of the
observed effect of TULA proteins is unique or other proteins
exist that also exert a negative effect on the HIV-1 life cycle by
interfering with its critical ubiquitylation-dependent events.
Finally, our results suggest that the expression of HIV-1 protein
is capable of reducing the endogenous level of TULA-2 (data
not shown), but whether or not this phenomenon represents a
counter-effect of HIV-1 on the cellular defense mediated by
TULA proteins has to be elucidated further.
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DNA constructs and siRNA
Expression constructs for V5-tagged wild-type and mutant
forms of TULA based on pAlterMAX described previously
(Feshchenko et al., 2004) were used as a source of the
corresponding cDNA. To obtain FLAG-tagged TULA, cDNA
encoding wild-type TULA short (Feshchenko et al., 2004) was
subcloned into the pFLAG 5a vector (Sigma, St. Louis, MO)
between EcoRV and KpnI restriction sites using the Advantage-
Hf2 polymerase (Clontech, Mountain View, CA). Forward and
reverse primers annealed with 15–18 nucleotides of the TULA
sequence and included the corresponding restriction site. To
introduce mutations, two oligonucleotides complementary to the
opposite strands of double-stranded DNA containing the
sequence to be mutated were designed to contain 15–18
nucleotides on either side of the mutation site. The mutagenesis
reactions were performed using the QuikChange Site-Directed
Mutagenesis Kit according to the manufacturer's recommenda-
tions (Stratagene, La Jolla, CA). To obtain Myc-tagged ABCE-1,
cDNA encoding human ABCE-1, which was previously
subcloned into the pcDNA3 vector (Martinand et al., 1999),
was amplified using the Expand High Fidelity PCR System
(Roche Applied Science, Indianapolis, IN). The forward primer
included an EcoRI restriction site and the coding sequence for the
Myc tag. The obtained fragment was ligated into the pAlterMAX
vector between its EcoRI and SmaI restriction sites. All resulting
constructs were verified by sequencing. To assess lentiviral
production, pCE, an HIV-based transfer plasmid encoding for
green fluorescent protein (GFP) (Hasham and Tsygankov, 2004);
pCMVΔ8.2, a packaging plasmid encoding for all HIV-1 proteins
except Env; and pMD.G, an envelope plasmid encoding for the
vesicular stomatitis virus glycoprotein (VSV-G) were used
(Naldini et al., 1996). The pGag-GFP plasmid was constructed
by PCR fusion of Rev-independent full-length gag gene to GFP
in pEGFP-N1 (Clontech) (Hermida-Matsumoto and Resh, 2000).
To deplete TULA-2/Sts-1, ON-TARGETplus SMARTpool
siRNA (L-008533-00; Dharmacon, Lafayette, CO) or an
equimolar mix of three individual siRNA (ID#121987, 121986,
34950; Ambion, Austin, TX) was used. To deplete c-Cbl, an
equimolarmix of two individual siRNA (ID#121527 and 121528:
Ambion) was used. Silencer Negative Control #1 siRNA
(Ambion) was used as negative control.
Cells and transfection
HEK293T and MAGI cells (both obtained from ATCC) were
cultured in DMEM supplemented with 2 mM L-glutamine,
100 IU/ml penicillin, 100 μg/ml streptomycin and 10% fetal
bovine serum (FBS). (MAGI are HeLa cells stably expressing
CD4 to facilitate HIV-1 infection and containing a genome-
integrated lacZ gene under control of the HIV-1 LTR promoter;
Kimpton and Emerman, 1992.) T-cell lines (Jurkat, MOLT4 and
SupT1—all obtained from ATCC) were cultured in RPMI1640,
which was supplemented as described above for DMEM. 293T
cells were transfected with purified plasmid DNA usingLipofectamine-2000 (Invitrogen/Life Technologies, Carlsbad,
CA) according to the manufacturer's recommendations and
harvested 36 to 72 h after transfection. When required, a GFP-
encoding expression plasmid (pEGFP-C2, Clontech) was co-
transfected with other expression plasmids to assess the effi-
ciency of transfection. Empty vector DNA was added to the
transfection mix, where necessary, to maintain total DNA
amount constant. MAGI cells were transfected using DMRIE-C
(Invitrogen/Life Technologies) according to the manufacturer's
recommendations. Forty-eight hours after transfection, cells
were harvested and re-seeded in multiple wells and infected
with the full-length replication-competent T-tropic (X4) HIV-1
strain RF at MOI ∼0.05. The numbers of cells in transfected
cultures were determined prior to infection. Supernatants of
infected cells were harvested 48 and 96 h post-infection and
frozen. The RF strain was obtained from the AIDS Research
and Reference Reagent Program (NIAID, Rockville, MD),
propagated in MOLT4 cells, purified from culture supernatants
using ultracentrifugation and titrated using a syncytia assay with
SupT1 cells as described previously (Raymond et al., 2006,
2004). All handling of HIV-1 was carried out in a BSL2+
facility using standard safety procedures.
Cell lysis and subcellular fractionation
Several lysis protocols were used to minimize non-specific
co-immunoprecipitation in each type of experiment. TNE buffer
(50 mM Tris, 150 mM sodium chloride and 2 mM EDTA;
pH 7.6) contained 1% NP-40 (Feshchenko et al., 1998). TNE-L
buffer contained 10mMTris (pH 7.4), 100mM sodium chloride,
50 mM potassium acetate, 10 mM EDTA and 1% NP-40
(Zimmerman et al., 2002). RIPA buffer was made by adding
SDS and sodium deoxycholate to TNE at the final concentrations
of 0.1 and 0.5%, respectively. In the experiments in which
subcellular localization of proteins was studied, cells were
homogenized prior to solubilization by being passed 10–20
times through a 19- to 25-gauge needle in hypotonic buffer
(10 mM Tris, 0.5 mM MgCl2; pH 7.5). Tonicity was restored
by adding 0.25 ml of high-salt buffer (same as hypotonic,
but containing 0.6 M sodium chloride) to 1 ml of hypotonic
homogenate, the resultant mix was centrifuged at 750×g for
5 min to remove unbroken cells and nuclei, and 0.5 mM EDTA
was added to post-nuclear supernatant. Finally, concentrated
TNE/β-octyl-D-glucoside (TNE/ODG) buffer was added to post-
nuclear supernatant to final concentrations of 1xTNE and 2%
ODG. In all cases except for studying subcellular fractionation,
cells or cell homogenates were solubilized for 30 min, and then
lysates were cleared by centrifugation (12,000×g, 5 min). All
buffers used for lysis/homogenization were supplemented with
inhibitors (10 μg/ml of each aprotinin, leupeptin and pepstatin,
0.5 mM PMSF, 10 mM sodium fluoride, 1 mM pervanadate),
and all lysis procedures were carried out at +4 °C. To study
subcellular distribution of proteins, cells were transfected and
homogenized as described above. Post-nuclear supernatant
was fractionated further using ultracentrifugation at 100,000×g
for 50 min at +4 °C. The obtained supernatant and pellet
represented cytosolic and membrane fractions, respectively. The
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solubilized in RIPA buffer for 30 min on ice.
Lentivirus production
To assess the effect of TULA and other proteins on HIV-1
production, 293T cells were grown to be ∼30% confluent on the
day of transfection. Purified plasmids required for lentivirus
production were transfected into 293T cells using calcium
phosphate, and virus-containing supernatants were harvested
and filtered through a 0.45-μm filter 3 days after transfection
(Hasham and Tsygankov, 2004). Virus production was assessed
using a single-round infectivity assay and biochemical analysis of
purified virions. The single-round infectivity assay was based on
flow cytometry-based enumeration of target cells infected with a
replication-incompetent virus encoding for GFP (Alroy et al.,
2005): filtered viral supernatants were added to Jurkat cells in 24-
well plates (2×105 cells/0.5 ml of medium per sample) in the
presence of 8 μg/ml polybrene, and cells were spin-inoculated at
800×g for 90 min at 32 °C. Jurkat cells were analyzed using
flow cytometry 2 days after spin-inoculation. The percentage of
infected (GFP+) cells showed the linear dependence on the
volume of supernatant in the range from 2 to 100 μl
(corresponding to the multiplicity of infection from ∼0.01 to
∼0.5). To assess virus production using Western blotting,
supernatant was centrifuged through a 20% sucrose cushion at
50,000×g for 90 min at +4 °C. To study the effect of protein
depletion on virus production, 293T cells were grown to be 20–
30% confluent and transfected with 150 nM total siRNA using X-
treme reagent (Roche Applied Sciences) at an RNA:reagent ratio
of 1:5 (w/v) in 2.5 ml of Opti-MEM per well of a 6-well plate.
Cells were re-transfected with 150 nM siRNA and the plasmids
required for virus production using calcium phosphate 24 h after
the initial siRNA transfection. Supernatant was collected 40 h
after the second transfection and analyzed as described above in
this section. Virus-producing cells were lysed for biochemical
analysis in all experiments when supernatants were harvested.
Immunofluorescence microscopy
HeLa cells were grown to be ∼80% confluent and trans-
fected with the plasmid encoding for HIV-1 Gag-GFP (for direct
analysis of fluorescence) or the pCMVΔ8.2 plasmid (for
immunofluorescence staining) and a pAlterMAX plasmid
encoding for either wild-type or ΔUBA TULA (1 μg of each
plasmid per well of a 6-well plate) using DMRIE-C as per the
manufacturer's recommendations. One day later, cells were
harvested and seeded on glass coverslips pre-coated with
fibronectin (10 μg/ml, overnight, +4 °C) at a confluency of
∼50%. Six hours later, the cells were washed, fixed with 3.7%
formaldehyde in PBS for 20 min at +4 °C with shaking. Cells
expressing HIV-1 Gag-GFP were washed in PBS containing 3%
FBS followed by equilibration buffer (Molecular Probes,
Eugene, OR). Cells expressing HIV-1 Gag were further incu-
bated in 50 mM glycine-containing PBS to quench free
aldehyde groups and permeabilized in PBS containing 2%
BSA and 0.1% Triton X-100. HIV-1 Gag, FLAG-TULA andCD63 were stained with the corresponding antibodies at room
temperature for 1 h. Polyclonal rabbit anti-HIV-1 p24 antibody
H6003-33E from US Biologicals (Swampscott, MA), anti-
FLAG M2 mouse monoclonal antibody (mAb) from Sigma and
anti-CD63 H5C6mousemAb fromBDPharmingen (SanDiego,
CA)were diluted in permeabilizing buffer at final concentrations
of 20, 5 and 2 μg/ml, respectively. Coverslips were extensively
washed with PBS and stained with the corresponding secondary
antibodies at room temperature for 1 h. Goat anti-mouse IgG-
FITC (Southern Biotech, Birmingham, AL) and bovine anti-
rabbit IgG-rhodamine (Santa Cruz Biotechnology, San Cruz,
CA) were used at the dilutions of 1:100 and 1:400, respectively.
The coverslips were mounted onto a slide with anti-fade
mounting solution (Molecular Probes). Cell images were ob-
tained using confocal microscopy (Leica DM IRE2 microscope
with a 100× objective).
Adenovirus
Adenoviruses expressing wild-type and mutant FLAG-
tagged TULA were constructed using the AdEasy Vector
System (Q-Biogene, Carlsbad, CA) essentially as described
previously (Fikaris et al., 2006). cDNA encoding FLAG-tagged
TULA was amplified using the Expand High Fidelity PCR
System (Roche Applied Science) with the corresponding cDNA
TULA (wild-type, W279L or ΔUBA) subcloned into pAlter-
MAX as templates. The forward primer annealed to the 18
nucleotides corresponding to the N-terminal end of TULA and
included a BamHI restriction site and the coding sequence for
the FLAG tag. The reverse primer annealed to the 17 nucleo-
tides corresponding to the C-terminal end of TULA and in-
cluded a stop codon and a SpeI restriction site. The introduced
sites were used to ligate the FLAG-TULA cDNA into the
pShuttle-CMV vector by generating sticky ends compatible
with those formed by digesting pShuttle-CMV with BglII and
XbaI. The resulting constructs were verified by sequencing
and used for recombination with adenoviral DNA in BJ5183
competent E. coli cells. QBI-293A cells were transfected with
recombinants and analyzed for adenovirus production using
plaque assay. The selected clones were propagated as per the
manufacturer's recommendations, and the titers of final prep-
arations were determined using plaque assay. LacZ-expressing
adenovirus was used as negative control.
Identification of TULA-associated proteins
293T cells were transfected with the FLAG-TULA expres-
sion plasmid, harvested, washed with PBS and lysed in CelLytic
buffer (Sigma) for 15 min at room temperature. Cell debris was
removed by centrifugation, and 1–3 mg of total protein from
FLAG-TULA-expressing or vector-transfected cells was incu-
bated with 20 μl anti-FLAG M2 affinity gel (Sigma) at 4 °C for
4 h. The beads were washed three times with CelLytic buffer,
and anti-FLAG-bound proteins were eluted from the beads with
0.1 M glycine (pH 3). Proteins eluted from the anti-FLAG beads
were separated on a one-dimensional Bis–Tris minigel and
stained in Simply Blue Coomassie (Invitrogen). After in situ
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data-dependent LC-MS/MS on an Agilent LC-MSD. Unin-
terpreted mass spectra were searched against a human non-
redundant protein database using Mascot (Matrix Science)
(Perkins et al., 1999). Errors used were 2.0 kDa on MS data and
0.8 kDa on MS/MS data.
Immunoprecipitation and immunoblotting
Total protein (1–3 mg) from whole cell lysate was incubated
with an antibody indicated (1–3 μg/sample) in a total volume of
1 ml and immunoprecipitated with 50 μl of Protein A Sepharose
(Amersham Biosciences, Piscataway, NJ) or 20 μl of Protein G
Agarose (Upstate Biotechnology, Lake Placid, NY) slurry.
Protein A Sepharose was used to precipitate rabbit antibodies,
whereas all other antibodies were precipitated using Protein G
Agarose. Proteins were separated using SDS–PAGE, trans-
ferred to nitrocellulose and probed with the corresponding
antibody at an appropriate dilution as indicated. The appropriate
peroxidase-conjugated secondary antibody was added, and
proteins were visualized using chemiluminescence. Anti-Myc
4A6 mouse mAb was purchased from Upstate Biotechnology.
Anti-ABCE1 NB400-116 rabbit polyclonal antibody was
purchased from Novus Biologicals (Littleton, CO). Anti-HIV-
1 Gag antibodies recognizing both p24 and unprocessed Pr55gag
(AG3.0 mouse mAb and sheep polyclonal antiserum, catalogue
#4121 and catalogue #287, respectively) were obtained through
the NIH AIDS Research and Reference Reagent Program
(Germantown, MD). Anti-p24 goat polyclonal antibody recog-
nizing only the processed p24 formwas purchased fromViroStat
(Portland, ME). Anti-p17 chicken polyclonal antibody recog-
nizing only p17 was purchased from Genway (San Diego, CA).
Anti-VLA2αmouse mAb was purchased from BD Biosciences.
Anti-GFP B-2 mouse mAb was purchased from Santa Cruz
Biotechnology. Anti-GAPDH 6C5 mouse mAb was purchased
from Research Diagnostics (Flanders, NJ). Anti-TULA and anti-
TULA-2 rabbit polyclonal antibodies were custom-produced by
Proteintech Group (Chicago, IL) against the peptides containing
amino acids 4–23 of TULA and 15–34 of TULA-2/Sts-1,
respectively, conjugated to KLH and affinity purified using the
corresponding antigen peptide.
Antigen capture enzyme-linked immunoassay (ELISA)
HIV-1 p24 protein was measured in cell supernatants using
an HIV-1 p24 Antigen ELISA kit from ZeptoMetrix (Buffalo,
NY) or SAIC (Frederick, MD). Briefly, p24 was captured by a
plate-immobilized anti-p24 antibody and detected using a
biotinylated anti-p24 followed by streptavidin-peroxidase
(ZeptoMetrix) or rabbit anti-p24 followed by anti-rabbit goat
IgG-peroxidase (SAIC). The amount of p24 in specimens was
quantified using its comparison to a standard curve.
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